Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers
Open Access
- 30 June 2020
- Vol. 12 (7), 1740
- https://doi.org/10.3390/cancers12071740
Abstract
Lung cancer (LC) causes the majority of cancer-related deaths. Circular RNAs (circRNAs) were reported to play roles in cancers by targeting pro- and anti-oncogenic miRNAs. However, the mechanisms of circRNAs in LC progression and their prognostic value of treatment response remain unclear. By using next generation sequencing (NGS) of LC cell lines’ transcriptomes, we identified highly overexpressed hsa_circ_0000190 and hsa_circ_000164 as potential biomarkers. By using the highly sensitive RT-ddPCR method, these circRNAs were shown to be secreted by cell lines and were detected in human blood. Clinical validation by RT-ddPCR was carried out on 272 (231 LC patients and 41 controls) blood samples. Higher hsa_circ_0000190 levels were associated with larger tumor size (p < 0.0001), worse histological type of adenocarcinoma (p = 0.0028), later stage (p < 0.0001), more distant metastatic organs (p = 0.0039), extrathoracic metastasis (p = 0.0004), and poor survival (p = 0.047) and prognosis. Using liquid biopsy-based RT-ddPCR, we discovered the correlation between increased hsa_circ_0000190 plasma level (p < 0.0001) and higher programmed death-ligand 1 (PD-L1) level in tumor (p = 0.0283). Notably, long-term follow-up of the immunotherapy treated cases showed that upregulated plasma hsa_circ_0000190 level correlated with poor response to systemic therapy and immunotherapy (p = 0.0002, 0.0058, respectively). Secretory circRNAs are detectable in blood by LB-based RT-ddPCR and may serve as blood-based biomarkers to monitor disease progression and treatment efficacy.Funding Information
- Ministry of Science and Technology, Taiwan (106-2320-B-075-002, 106-2320-B-075-002)
- Taipei Veterans General Hospital (V107B-017, V108D46-004-MY2-2, V108E-006-4)
This publication has 51 references indexed in Scilit:
- The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the LungsAmerican Journal of Clinical Oncology, 2015
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancerJournal of the Chinese Medical Association, 2013
- Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel SequencingClinical Chemistry, 2013
- Tumor Immunotherapy Directed at PD-1The New England Journal of Medicine, 2012
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A ReviewJournal of Experimental & Clinical Medicine, 2011
- MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProceedings of the National Academy of Sciences of the United States of America, 2011
- Coexpression of Oct4 and Nanog Enhances Malignancy in Lung Adenocarcinoma by Inducing Cancer Stem Cell–Like Properties and Epithelial–Mesenchymal TransdifferentiationCancer Research, 2010
- Selection of Invasive and Metastatic Subpopulations from a Human Lung Adenocarcinoma Cell LineAmerican Journal of Respiratory Cell and Molecular Biology, 1997